{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:25:51Z","timestamp":1790742351011,"version":"4.1.0"},"reference-count":84,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In this review, we analyzed existing literature regarding the use of Gonadotropin-releasing Hormone (GnRH) analogues (agonists, antagonists) as a co-treatment to chemotherapy and radiotherapy. There is a growing interest in their application as a prophylaxis to gonadotoxicity caused by chemotherapy and\/or radiotherapy due to their ovarian suppressive effects, making them a potential option to treat infertility caused by such chemotherapy and\/or radiotherapy. They could be used in conjunction with other fertility preservation options to synergistically maximize their effects. GnRH analogues may be a valuable prophylactic agent against chemotherapeutic infertility by inhibiting rapid cellular turnover on growing follicles that contain types of cells unintentionally targeted during anti-cancer treatments. These could create a prepubertal-like effect in adult women, limiting the gonadotoxicity to the lower levels that young girls have. The use of GnRH agonists was found to be effective in hematological and breast cancer treatment whereas for ovarian endometrial and cervical cancers the evidence is still limited. Studies on GnRH antagonists, as well as the combination of both agonists and antagonists, were limited. GnRH antagonists have a similar protective effect to that of agonists as they preserve or at least alleviate the follicle degradation during chemo-radiation treatment. Their use may be preferred in cases where treatment is imminent (as their effects are almost immediate) and whenever the GnRH agonist-induced flare-up effect may be contra-indicated. The combination treatment of agonists and antagonists has primarily been studied in animal models so far, especially rats. Factors that may play a role in determining their efficacy as a chemoprotective agent that limits gonadal damage, include the type and stage of cancer, the use of alkylating agents, age of patient and prior ovarian reserve. The data for the use of GnRH antagonist alone or in combination with GnRH agonist is still very limited. Moreover, studies evaluating the impact of this treatment on the ovarian reserve as measured by Anti-M\u00fcllerian Hormone (AMH) levels are still sparse. Further studies with strict criteria regarding ovarian reserve and fertility outcomes are needed to confirm or reject their role as a gonadal protecting agent during chemo-radiation treatments.<\/jats:p>","DOI":"10.3390\/ijms23042287","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T08:18:05Z","timestamp":1645431485000},"page":"2287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation"],"prefix":"10.3390","volume":"23","author":[{"given":"Georgios","family":"Valsamakis","sequence":"first","affiliation":[{"name":"Second University Department of Obstetrics and Gynecology, Aretaieion University Hospital, Athens Medical School, Ethnikon and Kapodistriakon University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-3077","authenticated-orcid":false,"given":"Konstantinos","family":"Valtetsiotis","sequence":"additional","affiliation":[{"name":"Second University Department of Obstetrics and Gynecology, Aretaieion University Hospital, Athens Medical School, Ethnikon and Kapodistriakon University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-6998","authenticated-orcid":false,"given":"Evangelia","family":"Charmandari","sequence":"additional","affiliation":[{"name":"First University Department of Paediatrics, Aghia Sophia Childrens Hospital, Athens Medical School, Ethnikon and Kapodistriakon University of Athens, 152 33 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lambrinoudaki","sequence":"additional","affiliation":[{"name":"Second University Department of Obstetrics and Gynecology, Aretaieion University Hospital, Athens Medical School, Ethnikon and Kapodistriakon University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8479-6517","authenticated-orcid":false,"given":"Nikolaos F.","family":"Vlahos","sequence":"additional","affiliation":[{"name":"Second University Department of Obstetrics and Gynecology, Aretaieion University Hospital, Athens Medical School, Ethnikon and Kapodistriakon University of Athens, 115 28 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","unstructured":"Australian Institute of Health and Welfare (2021). Cancer Data in Australia."},{"key":"ref_3","unstructured":"Cancer Research UK (2021, October 30). All Cancers (C00-C97 Excl. C44), Average Number of New Cases per Year and Age-Specific Incidence. Available online: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/age."},{"key":"ref_4","unstructured":"Global Cancer Observatory (2020). Estimated Number of New Cases in 2020, All Cancers, Females, Ages 0\u201344, International Agency for Research on Cancer."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/107327480801500107","article-title":"Current issues in adolescent and young adult cancer survivorship","volume":"15","author":"Soliman","year":"2008","journal-title":"Cancer Control. J. Moffitt Cancer Cent."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdv227","article-title":"Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma","volume":"26","author":"Meissner","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bpobgyn.2011.11.008","article-title":"Chemotherapy and fertility","volume":"26","author":"Blumenfeld","year":"2012","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ygyno.2019.09.012","article-title":"Fertility preservation in gynecologic cancers","volume":"155","author":"Taylan","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1089\/jwh.2015.5194","article-title":"Understanding Fertility in Young Female Cancer Patients","volume":"24","author":"Waimey","year":"2015","journal-title":"J. Womens Health (Larchmt)"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/(SICI)1097-0142(19990815)86:4<697::AID-CNCR20>3.0.CO;2-J","article-title":"Having children after cancer. A pilot survey of survivors\u2019 attitudes and experiences","volume":"86","author":"Schover","year":"1999","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/REP-12-0121","article-title":"What lies behind chemotherapy-induced ovarian toxicity?","volume":"144","author":"Shalgi","year":"2012","journal-title":"Reproduction"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/humrep\/16.9.1838","article-title":"Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia","volume":"16","author":"Bath","year":"2001","journal-title":"Hum. Reprod."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Karavani, G., Rottenstreich, A., Schachter-Safrai, N., Cohen, A., Weintraub, M., Imbar, T., and Revel, A. (2021). Chemotherapy-based gonadotoxicity risk evaluation as a predictor of reproductive outcomes in post-pubertal patients following ovarian tissue cryopreservation. BMC Women\u2019s Health, 21.","DOI":"10.1186\/s12905-021-01343-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0360-3016(90)90007-7","article-title":"Gonadal status and reproductive function following treatment for Hodgkin\u2019s disease in childhood: The Stanford experience","volume":"19","author":"Ortin","year":"1990","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Oktay","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_16","unstructured":"National Comprehensive Cancer Network (2020). NCCN Guidelines for Patients\u00ae Invasive Breast Cancer, NCCN Foundation."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00404-011-1874-1","article-title":"Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin\u2019s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT","volume":"284","author":"Montag","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.23736\/S0026-4784.19.04387-9","article-title":"Fertility preservation in female cancer patients: Current knowledge and future perspectives","volume":"71","author":"Findeklee","year":"2019","journal-title":"Minerva Ginecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s10815-021-02263-5","article-title":"Perspectives on the development and future of oocyte IVM in clinical practice","volume":"38","author":"Grynberg","year":"2021","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beem.2018.09.002","article-title":"Cryostorage and retransplantation of ovarian tissue as an infertility treatment","volume":"33","author":"Amorim","year":"2019","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_21","first-page":"1328","article-title":"Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review","volume":"45","author":"Hoekman","year":"2019","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"ref_22","unstructured":"European Society of Human Reproduction and Embryology (2021, October 30). Ovarian Stimulation for Fertility Preservation. ESHRE Ovarian Simulation for IVF\/ICSI. Available online: https:\/\/www.eshre.eu\/Guidelines-and-Legal\/Guidelines\/Ovarian-Stimulation-in-IVF-ICSI."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Practice Committee of the American Society for Reproductive Medicine (2019). Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: A committee opinion. Fertil. Steril., 112, 1022\u20131033.","DOI":"10.1016\/j.fertnstert.2019.09.013"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","article-title":"Gonadotropin-Releasing Hormone Agonists during Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients with Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient\u2013Level Data","volume":"36","author":"Lambertini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","unstructured":"Adolescent and Young Adult (AYA) Oncology (2021, October 30). NCCN (Guidelines Version 2.2022). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aya.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.1988.03720140043031","article-title":"The relationship of gonadal activity and chemotherapy-induced gonadal damage","volume":"259","author":"Rivkees","year":"1988","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fidler, M.M., Reulen, R.C., Winter, D.L., Kelly, J., Jenkinson, H.C., Skinner, R., Frobisher, C., and Hawkins, M.M. (2016). Long term cause specific mortality among 34\u2009489 five year survivors of childhood cancer in Great Britain: Population based cohort study. BMJ (Clin. Res. Ed.), 354.","DOI":"10.1136\/bmj.i4351"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Blumenfeld, Z. (2019). Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. Clin. Med. Insights Reprod Health, 13.","DOI":"10.1177\/1179558119870163"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Von Wolff, M., and Stute, P. (2017). Judging the Fertility Protective Effect of GnRH Agonists in Chemotherapy-It Is a Matter of Perspective. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00069"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1472-6483(11)60210-1","article-title":"Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: Mechanisms of action","volume":"5","author":"Ortmann","year":"2002","journal-title":"Reprod. BioMedicine Online"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/oxfordjournals.bmb.a072606","article-title":"GnRH analogues for contraception","volume":"49","author":"Fraser","year":"1993","journal-title":"Br. Med. Bull."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/13697137.2016.1225713","article-title":"Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity","volume":"19","year":"2016","journal-title":"Climacteric J. Int. Menopause Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bpobgyn.2006.08.002","article-title":"GnRH agonists vs. antagonists","volume":"21","author":"Tarlatzis","year":"2007","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.7150\/jca.31859","article-title":"GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer","volume":"10","author":"Zhong","year":"2019","journal-title":"J Cancer"},{"key":"ref_35","first-page":"2711","article-title":"GnRH agonist for gonadal protection during chemotherapy","volume":"30","author":"Falcone","year":"2015","journal-title":"Hum. Reprod."},{"key":"ref_36","first-page":"688","article-title":"Anti-M\u00fcllerian hormone: Ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Hum. Reprod."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12522-015-0227-3","article-title":"Anti-M\u00fcllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?","volume":"15","author":"Iwase","year":"2015","journal-title":"Reprod. Med. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"515.e1","DOI":"10.1016\/j.ajog.2021.06.052","article-title":"Anti-Mullerian hormone levels among contraceptive users: Evidence from a cross-sectional cohort of 27,125 individuals","volume":"225","author":"Hariton","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.2012.42.8185","article-title":"Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial","volume":"31","author":"Demeestere","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdr575","article-title":"Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial","volume":"7","author":"Behringer","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10245330600954072","article-title":"Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD)","volume":"12","author":"Giuseppe","year":"2007","journal-title":"Hematology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdq066","article-title":"No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group","volume":"21","author":"Behringer","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_43","first-page":"2912","article-title":"GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro","volume":"30","author":"Bildik","year":"2015","journal-title":"Hum. Reprod."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Anderson, R.A., and Su, H.I. (2020). The Clinical Value and Interpretation of Anti-M\u00fcllerian Hormone in Women with Cancer. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.574263"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0002-9378(12)91826-8","article-title":"The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: A prospective, randomized study","volume":"170","author":"Reinsch","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1210\/en.2005-0700","article-title":"Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5","volume":"147","author":"Kitajima","year":"2006","journal-title":"Endocrinology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Desaulniers, A.T., Cederberg, R.A., Lents, C.A., and White, B.R. (2017). Expression and Role of Gonadotropin-Releasing Hormone 2 and Its Receptor in Mammals. Front. Endocrinol., 8.","DOI":"10.3389\/fendo.2017.00269"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Scaruffi, P., Stigliani, S., Cardinali, B., Massarotti, C., Lambertini, M., Sozzi, F., Dellepiane, C., Merlo, D.F., Anserini, P., and Mastro, L.D. (2019). Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20236045"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/annonc\/mdv374","article-title":"Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies","volume":"26","author":"Lambertini","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2014Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lambertini, M., Del Mastro, L., Pescio, M.C., Andersen, C.Y., Azim, H.A., Peccatori, F.A., Costa, M., Revelli, A., Salvagno, F., and Gennari, A. (2016). Cancer and fertility preservation: International recommendations from an expert meeting. BMC Med., 14.","DOI":"10.1186\/s12916-015-0545-7"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ctrv.2013.12.001","article-title":"Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials","volume":"40","author":"Ceppi","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chen, H., Xiao, L., Li, J., Cui, L., and Huang, W. (2019). Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst. Rev., 3.","DOI":"10.1002\/14651858.CD008018.pub3"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian Suppression with Triptorelin during Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaoncol.2015.3251","article-title":"Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"Munhoz","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/annonc\/mds250","article-title":"Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: Menstruation and pregnancy outcomes","volume":"24","author":"Wong","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_58","first-page":"6847","article-title":"Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immu.unotherapy for Premenopausal Patients with High-risk Breast Cancer","volume":"35","author":"Recchia","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3892\/ijo.2014.2811","article-title":"LH-RH analogues in the treatment of young women with early breast cancer: Long-term follow-up of a phase II study","volume":"46","author":"Recchia","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.fertnstert.2012.07.1144","article-title":"Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation","volume":"98","author":"Blumenfeld","year":"2012","journal-title":"Fertil. Steril."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1634\/theoncologist.2009-0269","article-title":"Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist treatment","volume":"15","author":"Blumenfeld","year":"2010","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jnci\/djy185","article-title":"Final Analysis of the Prevention of Early Menopause Study (POEMS)\/SWOG Intergroup S0230","volume":"111","author":"Moore","year":"2019","journal-title":"J. Natl Cancer Inst."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.fertnstert.2007.02.010","article-title":"Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma","volume":"89","author":"Blumenfeld","year":"2008","journal-title":"Fertil. Steril."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPH.0000000000001144","article-title":"Triptorelin for Fertility Preservation in Adolescents Treated with Chemotherapy for Cancer","volume":"40","author":"Meli","year":"2018","journal-title":"J. Pediatric Hematol.\/Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000499535","article-title":"Gonadal Function Recovery and Fertility in Women Treated with Chemo- and\/or Radiotherapy for Hodgkin\u2019s and Non-Hodgkin Lymphoma","volume":"64","author":"Gini","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10815-015-0452-z","article-title":"Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues","volume":"32","author":"Huser","year":"2015","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2015-0223","article-title":"Gonadotropin-Releasing Hormone Agonist Cotreatment during Chemotherapy May Increase Pregnancy Rate in Survivors","volume":"20","author":"Blumenfeld","year":"2015","journal-title":"Oncologist"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/bmt.2016.150","article-title":"Ovarian function after hematopoietic cell transplantation: A descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning","volume":"51","author":"Phelan","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00254570","article-title":"Failure to preserve fertility in patients with Hodgkin\u2019s disease","volume":"19","author":"Waxman","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated with Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Tock, S., Jadoul, P., Squifflet, J.-L., Marbaix, E., Baurain, J.-F., and Luyckx, M. (2018). Fertility Sparing Treatment in Patients with Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00240"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1743-7563.2007.00089.x","article-title":"Ovarian preservation with gonadotropin-releasing hormone analog during chemotherapy","volume":"3","author":"Gilani","year":"2007","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_74","first-page":"269","article-title":"Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women with Breast Cancer: A Randomized Trial","volume":"306","author":"Boni","year":"2011","journal-title":"JAMA"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Lemos, C.N.C.D., Reis, F.M., Pena, G.N., Silveira, L.C., and Camargos, A.F. (2010). Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide. Reprod. Biol. Endocrinol., 8.","DOI":"10.1186\/1477-7827-8-51"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/1933719116682876","article-title":"A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model","volume":"24","author":"Knudtson","year":"2017","journal-title":"Reprod. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, X., Kang, X., Deng, Q., Cai, J., and Wang, Z. (2013). Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: A controlled experimental animal study. Reprod. Biol. Endocrinol., 11.","DOI":"10.1186\/1477-7827-11-16"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Tas, M., Oner, G., Ulug, P., Yavuz, A., and Ozcelik, B. (2019). Evaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-M\u00fcllerian hormone and histological analysis in a rat model using cisplatin. Arch. Med. Sci.","DOI":"10.5114\/aoms.2019.87540"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/humrep\/dei166","article-title":"Ovarian stromal blood flow in the prediction of ovarian response during in vitro fertilization treatment","volume":"20","author":"Ng","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1933719107310707","article-title":"Gonadotropin-Releasing Hormone in the Ovary","volume":"14","author":"Metallinou","year":"2007","journal-title":"Reprod. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000514445","article-title":"Is Anti-M\u00fcllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?","volume":"17","author":"Torrisi","year":"2021","journal-title":"Breast Care"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Huerta-Reyes, M., Maya-N\u00fa\u00f1ez, G., P\u00e9rez-Solis, M.A., L\u00f3pez-Mu\u00f1oz, E., Guill\u00e9n, N., Olivo-Marin, J.-C., and Aguilar-Rojas, A. (2019). Treatment of Breast Cancer with Gonadotropin-Releasing Hormone Analogs. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00943"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1095\/biolreprod52.2.365","article-title":"Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys","volume":"52","author":"Ataya","year":"1995","journal-title":"Biol. Reprod."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.critrevonc.2019.03.010","article-title":"European Recommendations for female Fertility preservation (EU-REFER): A joint collaboration between oncologists and fertility specialists","volume":"138","author":"Dolmans","year":"2019","journal-title":"Crit. Rev. Oncol.\/Hematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:22:46Z","timestamp":1760134966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":84,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23042287"],"URL":"https:\/\/doi.org\/10.3390\/ijms23042287","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]}}}